Patents by Inventor Bernard Meignier

Bernard Meignier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6641816
    Abstract: The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus recombinant and a vaccinal antigen, which is not a poxvirus. The immunological material may be any biological material useful as a vaccine e.g., a polypeptide characteristic of a pathogenic microorganism or associated with a tumoral disorder, a DNA plasmid encoding a peptide or a polypeptide characteristic of a pathogenic microorganism or a tumor-associated antigen, or an hapten coupled to a carrier molecule. The poxvirus may be a live, attenuated or inactivated virus or a recombinant virus. Recombinant virus may encode a heterologous polypeptide such as chemokines, cytokines or co-immunostimulatory molecules or an homologous polypeptide, which is immunologically cross reactive with the immunogenic polypeptide or peptide.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: November 4, 2003
    Assignee: Aventis Pasteur S.A.
    Inventors: Michel Chevalier, Bernard Meignier, Catherine Moste, Suryaprakash Sambhara
  • Publication number: 20010021384
    Abstract: The invention concerns the use of an immunogen specific of a pathogenic agent with a gateway in the buccal mucous membrane region, for producing a vaccine composition to be administered in the floor of the mouth in a human being so as to develop directly a local response in IgA antibodies and in B cells secreting IgA in the buccal mucous membrane, saliva and ganglions draining said mucous membrane. The invention also concerns a vaccine composition capable of being applied in the floor of the mouth in a human being to induce local and systemic immunity in IgA antibodies, substantially consisting of a material adhering or not to the buccal mucous membrane and containing an immunogen specific of the pathogenic agent with a gateway into the buccal mucous membrane.
    Type: Application
    Filed: December 21, 2000
    Publication date: September 13, 2001
    Inventors: Therese Jourdier, Catherine Moste, Bernard Meignier
  • Patent number: 5741493
    Abstract: The use, when preparing a vaccine composition containing a standard influenza virus vaccine, of an additive which consists of a core or core fraction of at least one influenza virus, especially a fraction containing protein M; and a vaccine composition thereby obtained. The use of said additive improves the vaccine's effectiveness.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: April 21, 1998
    Assignee: Pasteur Merieux Serums et Vaccins
    Inventors: Catherine Moste-Deshairs, Bernard Meignier